<DOC>
	<DOCNO>NCT01712997</DOCNO>
	<brief_summary>Previous study suggest combination exist therapy may effective pulmonary arterial hypertension ( PAH ) . However , study sequential combination therapy , example , add sildenafil previously prescribe bosentan . This kind therapy model enough PAH patient , especially New York Heart Association ( NYHA ) class Ⅲ Ⅳ . In randomized , multicenter study , investigator evaluate safety efficacy combine inhaled iloprost , prostacyclin analog , endothelin receptor antagonist bosentan treatment naive patient PAH compare bosentan monotherapy . Efficacy endpoint include change baseline 6-min-walk distance ( 6-MWD ) , modify ( NYHA ) functional class , hemodynamic parameter , time clinical worsening .</brief_summary>
	<brief_title>Study Initial Combination Bosentan With Iloprost Treatment Pulmonary Hypertension Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>age 10 80 treatment naive symptomatic PAH 6MWD 100425 rest mean pulmonary artery pressure great 25 mm Hg , pulmonary capillary wedge pressure le 15 mm Hg , pulmonary vascular resistance 240 dyn.s.cm5 great . Patients thromboembolic disease , untreated obstructive sleep apnea , portal hypertension , chronic liver disease renal insufficiency , leftsided unrepaired congenital heart disease , substantial obstructive ( FEV1/FVC &lt; 50 % predict ) restrictive ( total lung capacity &lt; 60 % predict ) lung disease Patients receive phosphodiesterase inhibitor prostanoids endothelin receptor antagonist</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Treatment</keyword>
</DOC>